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Aims: Amino acids, especially branched chain amino acids (BCAAs), have important regulatory 27 
roles in protein synthesis. Recently studies revealed that BCAAs protect against 28 
ischemia/reperfusion (I/R) injury. We studied the signaling pathway and mitochondrial function 29 
affecting a cardiac preconditioning of BCAAs. 30 
Main methods: An in vivo model of I/R injury was tested in control, mTOR+/+, and mTOR+/-. Mice 31 
were randomly assigned to receive BCAAs, rapamycin, or BCAAs + rapamycin. Furthermore, 32 
isolated cardiomyocytes were subjected to simulated ischemia and cell death was quantified. 33 
Biochemical and mitochondrial swelling assays were also performed.  34 
Key findings: Mice treated with BCAAs had a significant reduction in infarct size as a percentage 35 
of the area at risk compared to controls (34.1 ± 3.9% vs. 44.7 ± 2.6%, P = 0.001), whereas mice 36 
treated with the mTOR inhibitor rapamycin were not protected by BCAA administration (42.2 ± 37 
6.5%, vs. control, P = 0.015). This protection was not detected in our hetero knockout mice of 38 
mTOR. Western blot analysis revealed no change in AKT signaling whereas activation of mTOR 39 
was identified. Furthermore, BCAAs prevented swelling which was reversed by the addition of 40 
rapamycin. In myocytes undergoing simulated I/R, BCAA treatment significantly preserved cell 41 
viability (71.7 ± 2.7% vs. 34.5 ± 1.6%, respectively, p < 0.0001), whereas rapamycin prevented this 42 
4 
 
BCAA-induced cardioprotective effect (43.5 ± 3.4% vs. BCAA, p < 0.0001).  43 
Significance: BCAA treatment exhibits a protective effect in myocardial I/R injury and that mTOR 44 
plays an important role in this preconditioning effect. 45 
Keywords 46 
Amino acid, Ischemia, Reperfusion, mTOR, Mitochondria  47 
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1. Introduction  48 
Ischemia/reperfusion (I/R) injury in the myocardium significantly affects morbidity and 49 
mortality. Various preconditioning methods have been discovered that prevent cardiac I/R injury. 50 
Murry et al. first reported that brief ischemic episodes provide cardioprotective effects against 51 
subsequent ischemic injury [1]. In addition to ischemia, several pharmacologic agents such as 52 
volatile anesthetics, opioids, and organic nitrate esters provide myocardial preconditioning effects 53 
[2-6]. Signal transduction pathways involved in cardiac preconditioning are believed to include the 54 
connection of G proteins and several mediators including adenosine. This causes the activation of 55 
protein kinase C via activation of phospholipase C and phospholipase D and initiates a downstream 56 
signaling cascade involving the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, release of 57 
reactive oxygen species, and activation of endothelial and inducible nitric oxide synthase. It also 58 
inhibits the opening of the mitochondrial permeability transition pore (mPTP) or the activation of 59 
mitochondrial ATP-sensitive potassium channels [7]. 60 
Recent advances in our understanding of the translation mechanism and its control have 61 
facilitated studies at the molecular level into the regulation of protein synthesis by nutrients. Amino 62 
acids, which belong to one class of nutrients [8], have important regulatory roles in protein 63 
synthesis. Of all amino acids, the branched-chain amino acids (BCAAs), a group of essential amino 64 
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acids comprised of valine, leucine, and isoleucine, have a unique role in this process [9]. Previous 65 
studies in rats demonstrated that BCAAs have protective effects against I/R injury in various 66 
organs, including the kidney and the liver [10, 11]. However, the effects of BCAAs in the ischemic 67 
myocardium are still unclear. In this study, we examined the signaling pathways and mitochondrial 68 
functions related to cardioprotective effects of BCAAs in cardiac I/R injury.   69 
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2. Material and methods 70 
 71 
2.1. Animals 72 
 All animals were treated in compliance with the Guidelines for Proper Conduct of Animal 73 
Experiments and Related Activities and the Guideline for Care and Use of Lab Animals at 74 
Tokushima University (Tokushima, Japan). Animal use protocols were approved by the Animal 75 
Care and Use Committee, Tokushima University (Tokushima, Japan). Male C57BL/6 mice (21-26 76 
g) and Wistar rats (250-300 g) were purchased from Japan SLC Inc. (Hamamatsu, Japan), and 77 
mTOR+/− mice were created as reported previously [12]. The animals were kept on a 12-hour light-78 
dark cycle in a temperature-controlled room and randomly assigned to treatment groups by an 79 
independent observer.  80 
 81 
2.2. Antibodies and BCAAs  82 
The following primary antibodies were used in this study in a 1:1000 dilution: polyclonal 83 
antibodies to Akt, phospho-Akt (Ser473), GSK3β, phospho-GSK3β (Ser9), mTOR, phospho-mTOR 84 
(Ser2448), Cell Signaling Technology (Danvers, MA); and glyceraldehyde 3-phosphate 85 
dehydrogenase (GAPDH), Santa Cruz Biotechnology (Dallas, TX). BCAAs were purchased from 86 
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Sigma Aldrich (St Louis, MO). Cell survival was investigated at 1mM and 20mM doses to identify 87 





Supplementary Figure 1.  93 
Cell survival was investigated at 1mM and 20mM doses to identify optimal dosing 94 
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2.3. Genotyping of mTOR kinase domain knockout mice by polymerase chain reaction (PCR) 95 
Mouse genomic DNA was extracted from tail tips. The concentration of cDNA was 96 
determined and adjusted for real-time PCR analysis, which was performed on an MJ Research 97 
Opticon 2 (Bio-Rad, Hercules, CA) in triplicate with the iQ SYBR Green Supermix (Bio-Rad). A 98 
sense primer, finTOR-k-tailu 6671 (5’-GCG GCA GGA TGA ACG AGT GAT GC-3’), was 99 
designed from exon 47 to amplify both the wild-type and targeted loci. An antisense primer, βgeo-100 
screening 1 (5’-AAT GGG CTG ACC GCT TCC TCG TGC TT-3’), was designed from the βgeo 101 
cassette to amplify the targeted locus. Another antisense primer, TOR-kin-tail-L 20636 (5’-GTG 102 
ATC CGC CTG CCT CTG CCT CCT GT-3’), was designed from intron 47 to amplify the wild-type 103 
locus. Amplification with these three primers produced an 803-bp band from the wild-type locus 104 
and a 468-bp band from the targeted locus.  105 
 106 
2.4. In vivo ischemia/reperfusion experiments 107 
Surgery was performed as previously described [4]. Briefly, mice were anesthetized with 108 
pentobarbital sodium (80 mg/kg ip) were mechanically ventilated with oxygen. Cardiac 109 
catheterization via the right carotid artery was performed with a Microtip pressure transducer 110 
(Millar Instruments Inc., Houston, TX) to examine hemodynamical change, and ischemia was 111 
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produced by occluding the coronary artery. After 30 min of occlusion, the ligature was released, and 112 
the heart was reperfused for 2 h [13]. Mice were randomly assigned to receive either a BCAA 113 
cocktail in saline (0.14 g/kg iv) or vehicle 30 minutes before the ischemic injury. Some mice were 114 
treated with rapamycin (mTOR inhibitor; 5.0 mg/kg iv) 45 min before the ischemia.  115 
After reperfusion, the coronary artery was again occluded, and the area at risk (AAR) was 116 
determined by staining with 1% Evans blue. The heart was immediately excised and cut into 1-mm 117 
slices. The left ventricle was counterstained with 1% 2,3,5-triphenyltetrazolium chloride. After 118 
overnight storage in 10% formaldehyde, slices were weighed and visualized under a microscope 119 
equipped with a digital camera (D90, Nikon Imaging, Japan). The images were analyzed, and the 120 
area at risk and the infarct size were determined by planimetry as previously described [14].  121 
 122 
2.5. Serum cardiac troponins 123 
Cardiac troponin I levels in the serum were measured using a High Sensitivity Mouse 124 
Cardiac Troponin-I ELISA Kit (Life Diagnostics, West Chester, PA) as described before [15]. 125 
 126 
2.6. Mitochondrial isolation and swelling assay  127 
C57Bl/6 mice were injected with vehicle, BCAAs, and with rapamycin. Hearts were then 128 
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harvested after various treatments and I/R experiment. Hearts containing 4 mL sucrose buffer A 129 
(300 mM sucrose, 10 mM Tris-HCl, 2 mM EGTA and 5 mg/mL bovine serum albumin, pH 7.4) 130 
were homogenized, and the homogenate was centrifuged at 2000×g for 2 min at 4°C to remove cell 131 
debris. The supernatant was further centrifuged at 10 000×g for 30 min at 4°C to sediment impure 132 
mitochondria. The mitochondrial pellet was purified and washed as described previously [16]. 200 133 
µL of mitochondria in sucrose buffer B (300 mM sucrose, 10 mM Tris-HCl, pH 7.4) was loaded in 134 
to a 96-well plate and challenged with 100 µM CaCl2 (2 mg/mL protein concentration). The 135 
absorbance was measured 600 times every 2 s at 520 nm using a VarioSkan Flash 136 
spectrophotometer (Thermo Scientific, Japan). In some experiments, mitochondria were pretreated 137 
with 250 nM cyclosporine A to inhibit CaCl2-induced mitochondrial swelling to confirm the mPTP 138 
dependence of the calcium-induced swelling [17, 18]. 139 
 140 
2.7. Isolation and treatment of adult rat cardiac myocytes 141 
Cardiac myocytes were isolated by cardiac retrograde aortic perfusion and collagenase 142 
treatment as described previously [19]. Cardiac myocytes were plated on laminin-coated 12-well 143 
plates, allowed to incubate for 24 h, and then subjected to various experimental conditions at 37 °C. 144 
Culture medium was changed to amino acid-free Dulbecco’s modified Eagle’s medium (DMEM) 6 145 
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hours prior to experimentation to washout any residual amino acids found in the maintenance 146 
medium. Simulated ischemia was induced in metabolic chamber by replacing the air with a 95% N2 147 
and 5% CO2 gas mixture at 2 L/min and the media with glucose-free media (glucose-free DMEM, 148 
Invitrogen) for 60 min. This was followed by 60 min of simulated reperfusion by replacing the 149 
media with amino acid-free DMEM and incubating the cells with 21% O2 and 5% CO2. Before the 150 
simulated ischemia/reperfusion (SI/R), cardiac myocytes were exposed with or without rapamycin 151 
(20 nM). This was followed by exposure to media with or without BCAA dissolved in PBS (2 mM) 152 
for 30 min prior to SI/R. Cell death was quantified by counting trypan blue-stained cells with the 153 
results expressed as a percentage of total survival [20].  154 
 155 
2.8. Immunoblots 156 
Lysates were separated by SDS-PAGE on 10% polyacrylamide precast gels (Invitrogen) 157 
and transferred to polyvinylidene difluoride membranes by electroelution. Membranes were 158 
blocked in 20 mM TBS-Tween (1%) containing 5% skim milk and incubated with primary 159 
antibodies overnight at 4°C. Immunolabeled blots were visualized using horseradish peroxidase-160 
conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX) in a 1:2000 dilution and 161 
visualized by enhanced chemiluminescence reagent (GE Healthcare, Waukesha, WI) [21, 22]. 162 
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2.9. Statistics 163 
All results were analyzed by observers blinded to the experimental conditions. Data are 164 
presented as the means ± standard deviation. Differences between treatment groups were tested for 165 
statistical significance by one-way analysis of variance followed by Bonferroni’s post hoc test. A 166 
difference was considered significant if the probability value was <0.05.   167 
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3. Results  168 
3.1. Involvement of mTOR in BCAA-induced cardiac protection 169 
Among the treatment group, there were no differences in the baseline hemodynamics 170 
(heart rate, arterial blood pressure, or rate pressure product) before the occlusion (data not shown). 171 
No differences were observed in the area at risk as a percentage of the left ventricular area between 172 
the groups (data not shown). Mice treated with BCAAs had a significant reduction in infarct size as 173 
a percentage of the area at risk compared to controls (34.1 ± 3.9% vs. 44.7 ± 2.6%, n = 7/group, P = 174 
0.001). Pretreatment with the mTOR inhibitor rapamycin prevented in mice this protection by 175 
BCAAs (42.2 ± 6.5%, n = 7, P = 0.015 vs. control, Fig. 1A and Supplementary Figure 2). We 176 
confirmed these effects by measuring serum troponin I levels, a marker of cardiac myocyte damage 177 
(Fig. 1B). Additionally, the protection produced by BCAA treatment was also eliminated in 178 
mTOR+/− mice (44.1 ± 6.3%, n = 7, Fig. 1C and D). These results strongly suggest that the 179 
cardioprotective effects of BCAA depend on intact mTOR signaling. Of note, troponin I levels in 180 
sham mice with BCAAs and with and without rapamycin showed no significant differences (Data 181 






Figure 1. Branched-chain amino acids (BCAAs) protects the mouse myocardium from ischemic 184 
injury.  185 
Branched chain amino acids (BCAAs) protects the mouse myocardium from ischemic injury. (A) 186 
Infarct size (IS) expressed as a percentage of area at risk (AAR). The IS was reduced by BCAA 187 
treatment; however, additional rapamycin pretreatment abolished the BCAA-induced protection in 188 
mice. (B) Cardiac troponin I, a serum marker of myocardial damage, was significantly decreased in 189 
BCAA-treated mice, but this cardioprotective effect was eliminated by rapamycin. (C) The IS was 190 
reduced in BCAA-treated mTOR+/+, but not in mTOR+/− mice. (D) BCAAs induced a decrease in 191 







Supplementary Figure 2. 195 
Representative photos of infarct size with BCAA, Rapa, or BCAA+Rapa. White – infarct size, Blue 196 




3.2. Mitochondrial permeability transition pore  201 
The effects of BCAA on Ca2+-induced swelling in isolated mouse heart mitochondria are 202 
shown in Fig. 2. The addition of 100 μM Ca2+ caused a significant decrease in absorbance, 203 
indicating mitochondrial swelling. The Ca2+-induced swelling was inhibited by cyclosporine A, an 204 
mPTP inhibitor. Under these conditions, BCAA significantly attenuated the Ca2+-induced swelling 205 
compared with the control. Rapamycin was effective in inhibiting BCAA induced protection. These 206 




Figure 2. Sensitivity to mitochondrial permeability transition pore formation according to 209 
Ca2+-induced mitochondrial swelling. 210 
Branched-chain amino acids (BCAAs) inhibited mitochondrial swelling caused by ischemia/ 211 
reperfusion injury. BCAA-treated mitochondria (BCAA) presented substantially less swelling 212 
compared to untreated (Control) and rapamycin-treated (Rapamycin + BCAA) mitochondria when 213 
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exposed to calcium chloride. Cyclosporine A was used as a control experiment to inhibit CaCl2-214 
induced mitochondrial swelling, confirming the dependence of the calcium-induced swelling on the 215 
activity of the mitochondrial permeability transition pore.  216 
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3.3. BCAA improves the cell survival after simulated ischemia/reperfusion 217 
To more accurately assess myocyte survival under controlled experimental conditions, we 218 
next examined the cardioprotective effects of BCAA in isolated rat cardiac myocytes in response to 219 
SI/R (Fig. 3). Adult cardiac myocytes under control conditions exhibited no substantial signs of cell 220 
death. In myocytes undergoing SI/R, cells pretreated with BCAA significantly retained viability 221 
compared to cells without pretreatment (71.7 ± 2.7% vs. 34.5 ± 1.6%, respectively, P < 0.0001), 222 
whereas the addition of rapamycin to the pretreatment prevented this BCAA-induced 223 







Figure 3. The survival rate of adult cardiac myocytes exposed to simulated 227 
ischemia/reperfusion.  228 
Branched-chain amino acids (BCAAs) improve the survival rate of adult cardiac myocytes exposed 229 
to simulated ischemia/reperfusion, but rapamycin inhibited this preventive effect. Wortmannin, a 230 
phosphatidylinositol-3-kinase (PI3K) inhibitor, does not affect the cardiac protection induced by 231 
BCAAs.  232 
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3.4. Signaling pathways involved in BCAA-induced cardiac protection  233 
To investigate the mechanism for cardiac protection induced by BCAA, we examined the effect of 234 
BCAA on the phosphorylation of the cytoprotective kinase Akt and its downstream substrate 235 
GSK3β as well as on the phosphorylation of mTOR (Fig. 4). BCAA treatment caused neither Akt 236 
nor GSK3β phosphorylation. By contrast, mTOR was phosphorylated after BCAA pretreatment but 237 
not after pretreatment with BCAA in the presence of rapamycin. Thus, the cytoprotective effects of 238 
BCAA likely depend on mTOR activity but not on Akt/GSK3β signaling. Additionally, following 239 




  242 
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Figure 4. Immunoblots for Akt, phospho-Akt, GSK3β, phospho-GSK3β, mTOR, phospho-243 
mTOR, phospho-S6K and S6K.   244 
Immunoblots for Akt, phospho-Akt, GSK3β, phospho-GSK3β, mTOR, and phospho-mTOR, pS6K 245 
and S6K. Branched-chain amino acids (BCAAs) significantly increased phosphorylation of mTOR 246 
and pS6K without altering the phosphorylation of Akt or GSK3β proteins expression in lysed hearts. 247 
Pretreatment with rapamycin blocked BCAA-mediated activation of mTOR. Values are expressed as 248 
mean ± standard deviation. * represents P < 0.05 vs. control.  249 
27 
 
4. Discussion 250 
In the current study, BCAAs significantly decreased the infarct size, whereas the mTOR 251 
inhibitor rapamycin prevented this protective effect using in vivo mouse model of regional 252 
myocardial ischemia and reperfusion. BCAA treatment also preserved cell viability after simulated 253 
I/R in cardiac myocytes. However, the PI3K inhibitor wortmannin did not interfere with the 254 
cardioprotective effect induced by BCAAs. Moreover, the immunoblot analysis demonstrated that 255 
BCAA led to mTOR phosphorylation, which was prevented by the addition or rapamycin. However, 256 
phosphorylation of Akt or GSK3β was not observed after BCAA pretreatment. These results suggest 257 
that mTOR signaling but not PI3K/Akt/GSK3β pathways may act as a key effector of myocardial 258 
protection by BCAA.  259 
mTOR is a serine/threonine kinase in the PI3K-related kinase family that plays a vital role 260 
in cell growth, survival, and metabolism. mTOR and its downstream signaling networks regulate 261 
autophagy, protein synthesis, cell polarity, and cytoskeletal organization [24]. mTOR complex 1 262 
(mTORC1) and 2 are known as the catalytic subunits of two distinct protein complexes. mTORC1 263 
is defined by its three core components: mTOR, regulatory protein associated with mTOR (raptor), 264 
and mammalian lethal with Sec13 protein [25-27]. 265 
Over the last few years, studies have shown that growth factors modulate mTORC1 266 
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activity through the phosphorylation of insulin receptor substrate 1 and the stimulation of PI3K, 267 
which in turn leads to the activation of Akt [28]. Amino acids activate mTORC1 by recruitment to 268 
the surface of lysosome, which is caused by Regulator-Rag complex combining to raptor [29]. 269 
Leucine, one of the three branched chain amino acids, is supposed to relate to the regulation of 270 
mTORC1 through cytosolic sensors such as leucyl-tRNA synthetase and Sestrin 2 [30]. Previous 271 
studies indicate that amino acids induced cytoprotective effects by reducing the inflammatory 272 
response [11]. BCAAs respond to several cells signaling pathways mainly through the activation of 273 
the mTOR axis and mTOR relates to myocardial I/R injury through multiple signaling pathways 274 
such as AMP-activated protein kinase (AMPK)/mTOR or PI3K/Akt/mTOR pathway associated 275 
with autophagy [31, 32]. In this study, there is no significant difference of infarct size as a 276 
percentage of the area at risk or cTn1 in control of both mTOR+/+ and mTOR+/- mice. This may 277 
result from some other signaling pathways known to show the protective effect on I/R injury in the 278 
heart. As one of the important intracellular signaling pathways of cardiac preconditioning, PI3K and 279 
its downstream target Akt, are also involved in the regulation of oxidation, inflammatory responses, 280 
and apoptosis. The PI3K/Akt/GSK3β-dependent signaling pathways have been demonstrated to 281 
result in the attenuation of myocardial I/R injury [33-37]. On the other hand, the present study 282 
suggests that mTOR signaling pathway, not PI3K/Akt/GSK3β-dependent signaling pathways may 283 
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be important in the cardioprotective effects of BCAA treatment. To identify the mechanisms 284 
involved in this protection in detail, further studies are needed. 285 
In the current study, we also evaluated the effects of BCAAs on the improvement of 286 
mitochondrial functions. Cyclosporine A, an mPTP inhibitor, inhibited Ca2+-induced swelling. The 287 
Ca2+-induced swelling of mouse heart mitochondria was also abolished by BCAA. This result 288 
suggests that the opening of the mPTP was decreased by BCAA treatment, resulting in the 289 
prevention of mitochondrial-mediated cell death. In addition, our data demonstrated that rapamycin 290 
effectively attenuated this preventive effect.   291 
Mitochondria play a central role in molecular events, leading to tissue damage after 292 
pathological stimulation such as ischemia [38, 39]. mTOR is known to control mitochondrial 293 
dynamics [40]. mTOR binds and regulates the voltage-dependent anion channel proteins [41], 294 
which are an important component of the mPTP in the outer mitochondrial membrane. Several 295 
studies showed inhibition of mTOR activity provoked a decrease in mPTP permeability [42]. 296 
mTOR activation caused by BCAAs may preserve mitochondrial-mediated cell death triggered by 297 
unknown signaling pathways that are related to Ca2+-induced swelling in cardiac I/R injury. The 298 
mPTP is a large-conductance mega-channel found at the contact sites between the inner and outer 299 
mitochondrial membranes [39]. The long-term opening of this channel dissipates the inner 300 
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mitochondrial membrane potential, results in matrix swelling, rupture of the outer mitochondrial 301 
membrane, and the release of cytochrome C from the intermembrane space into the cytosol where it 302 
activates proteolytic processes and initiates cellular disintegration. Inner membrane depolarization, 303 
high concentrations of inorganic phosphate, ROS, and reactive nitrogen species are all present 304 
during myocardial ischemia and more importantly during reperfusion and facilitate mPTP opening 305 
[43, 44]. In contrast to permanent mPTP opening, a transient channel activity may serve a 306 
physiological function in ROS homeostasis and calcium release, and transient mPTP opening is 307 
indeed cardioprotective during ischemic preconditioning [39].   308 
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5. Conclusions 309 
We show that BCAA treatment reduces cardiac I/R injury and that mTOR activity plays a 310 
significant role in this preconditioning effect by BCAAs, which is separate from and acts in parallel 311 
to PI3K/Akt activation.   312 
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